Lisinoplus 10+12,5 mg tabletter Danimarka - Daniż - Lægemiddelstyrelsen (Danish Medicines Agency)

lisinoplus 10+12,5 mg tabletter

stada arzneimittel ag - hydrochlorthiazid, lisinoprildihydrat - tabletter - 10+12,5 mg

Lisinoplus 20+12,5 mg tabletter Danimarka - Daniż - Lægemiddelstyrelsen (Danish Medicines Agency)

lisinoplus 20+12,5 mg tabletter

stada arzneimittel ag - hydrochlorthiazid, lisinoprildihydrat - tabletter - 20+12,5 mg

Febuxostat Mylan Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

febuxostat mylan

mylan pharmaceuticals limited - febuxostat - hyperuricemia; arthritis, gouty; gout - antigout præparater - febuxostat mylan er indiceret til forebyggelse og behandling af hyperurikæmi hos voksne patienter, der gennemgår kemoterapi for hæmatologiske maligniteter ved mellemliggende risici for tumor lysis syndrome (tls). febuxostat mylan er indiceret til behandling af kronisk hyperuricaemia i forhold, hvor urat deposition har allerede fundet sted (herunder en historie, eller tilstedeværelsen af, tophus og/eller arthritis urica). febuxostat mylan er indiceret hos voksne.

Vildagliptin/Metformin "Stada" 50+850 mg filmovertrukne tabletter Danimarka - Daniż - Lægemiddelstyrelsen (Danish Medicines Agency)

vildagliptin/metformin "stada" 50+850 mg filmovertrukne tabletter

stada arzneimittel ag - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg

Vanflyta Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.